What did living through that teach you, um, about businesses and, and equipping entrepreneurs moving forward?

Well, I, I, I would never do it again, uh, to be honest.

Uh, it was, uh, very, very, uh, complicated.

Um, it was, uh, such an exciting, um, activity to do.

Um, what I, what I realized is that, uh, the business, uh, for me changed completely, so I, I regard myself as an entrepreneur.

Um, I'm constantly trying to solve problems, uh, and that's where my mind works best.

Uh, and that was exciting for me.

You've written in the past that the BBBEE Act pushes larger companies to put 3% of after-tax profit and 30% of their supply chain spend towards small businesses, and you've called that combination, quote, "a success formula." Are you seeing it working in the market?

What separates the ideas from the ones who make it and the ones that don't?

It's a long jump and a difficult road for any sort of idea in its genesis to go into being a viable company.

And there's lots of organizations that have been assisting me and that assist inventors take their ideas through.

It's very difficult though, because you first of all got to prove it works.

You've got to convince some business people to get on board.

There's a lot of validation required for people to open their wallets.

So within New Zealand, I think we're lucky.

was just wondering, in 10 years' time, what kind of health technology do you think we'll take for granted that seems futuristic now?

What's that all about?

Clearly, we've got climate change, and the last three springs have been hot and dry, and, uh, spring crops in particular on this light land have suffered.

And Phil Howell from NIAB said chickpeas will take all the heat that you can throw at them, and clearly that seems to be the case.

The problem is with growing chickpeas in the UK traditionally has been cooler, damper summers not suiting the growth cycle of that crop and them not coming to harvest in a sensible time.

So the weather conditions seem to be more suited to the crop now, but with some innovative, um, methods of growing them, i.e. using companion cereal species to synchronize the ripening of the chickpeas with the early ripening cereals seem to be a logical thing to try with this particular crop, having found that it works really well with oats and beans or beans and barley and other bi-crops that I've grown on the farm already.

So I'm familiar with the technique and was very happy to trial it to make this crop work.

When do you envisage that happening?

If the weather continues as it has, and we've just had heat wave three and the forecast is for heat wave four, in two weeks' time, they're gonna be actually very near harvesting, which is sort of a pleasant surprise because I-- when I went into this, the fear was that it would be a September harvested crop.

Ju- just talk us through that decision because quite a big decision to, to sort of leave school and, and go into employment.

Um, yeah, I don't, I don't think it was ever really a decision.

I think it was just a, a general drifting away from education.

Um, I, I went to state school in South London and I think, you know, me and my peer groups, you know, we were, you know, bright enough but probably not clever enough to, to kind of understand the privilege we had of education and, you know, probably took it for granted a little bit.

Um, and I think, yeah, by the time I got to sort of sixth form, it, it really wasn't for me at that stage of my life.

So, um, yeah, I went to college and, and I kind of really just sort of, you know, I'd get, particularly in the summer, you get offered to play for sort of wandering sides for cricket.

Um, you know, go and do days laboring or something like that really.

Can you just take us through some of the other sponsorships and partnerships that you're, you're working with? And is it all sort of the s- a similar setup to the, what you're providing at Sweden?

That's S E R V a L.com slash tickets.

I were, were disarmed and disabled.

So the first point is that the judge treated that motivation as an aggravating factor.

Now, we have to be very clear about what that means.

That means he sees that as a factor.

And in this particular case, the aggravation is that there is a terrorism connection.

And the reasoning is quite complex.

What do you think of that kind of chain of, well, maybe what do you think of that chain of sort of reasoning about the relationship between these cases, you know, this coming week? And what do you think about rather the other kind of case, which is that there's some very close interconnection between know terrorism definitions terrorism bans and terror and terror connection uh uh sentencing here

Tell me what you think, how are these drugs working to reduce inflammation markers?

So I'm going to kind of promote myself.

I did a short article on the blog called Taming the Fires, and it is about that.

It's about why is this probably helping? It has to do with...

I don't want to get too deep into it, but yeah, basically it's telling your immune system to kind of calm down a little bit.

So yes, HSCRP is a kind of relative broad marker for inflammation, but it's also telling other inflammatory markers.

So there's something called TNF-alpha.

sure impacted what it's doing in that short amount of time because as you're kind of laying out some of these extra things that glp1 seems to do with inflammation it that little short amount of time that little window is very impactful

But so d- I wanna hear your little story how you got in, into this.

Um, uh, so I was, uh, I was in nurse practitioner school a few years back.

Uh, I, I did my master's thesis on, uh, on how GLP-1 meds, uh, uh, act, uh, both centrally and, uh, and peripherally, like, uh, you know, basically how it's using, uh, you know, vagal nerve, uh, uh, you know, afferent vagal nerve feedback, yada, yada.

Won't get into that.

Um, and, uh, it just so happened, uh, uh, one of the, uh, lead investigators for the phase two trial was in town and, uh, and my, uh, preceptor at the time for, for family medicine was like, "Hey, you wanna talk to him?" You know? And so I talked to him and he was like, you know, "Hey, we're, we're recruiting for phase three right now.

If you wanna lose some weight, uh, you know, give this site a call." So I called the site and, uh, and kinda the rest is, is history.

I, I was, uh, my BMI was about 34, almost 35, and, and now sitting here, uh, my BMI is 24.

You, you jumped in, went in a trial.

... available time to get back.

I think if an athlete is telling you that, that they don't feel ready, you would be a fool not to listen to that.

Um, so more of the research that's coming out now is, is proving really that the tests, the battery of tests that we're doing clinically in the rehab period are not sufficient really to, to tell whether a player is totally recovered, and especially neurocognitively.

Um, so we can do all the strength testing, force plate testing for strength and asymmetry and power and things.

But another interesting talk from last week, they, um, they used functional MRI on the brain to show that-

that-Even a simple task for a player who'd injured their ACL, ex- like they were in the MRI scanner as they were asked to extend their knee, and the injured player's cort- cortex in the brain just lights up, so that they're having to use so much of their brain function just to do a simple maneuver.

And the, the research goes on to show that, um, when we're sending players back to play, they haven't...

But as you say, the injury rates are probably, you know, they may be similar, but perhaps before they were massively underreported, so patients were having wrist injuries, ankle injuries, and not really r- telling the medical team 'cause there was no one there to tell 'cause they were busy dealing with the, you know, the, the ACL rehabilitation.

He says he left mostly to be free of the demands, but ...

Well, I was just hanging out with the cat, and it was a little lonely, honestly.

[laughs] It was a little lonely.

Why not?

I still feel like I'm contributing meaningfully to a place I really care aboutI wanted to go through some of my to-do list for the week.

Okay.

How, you know, one wears that hat of, of thinking about, you know, strategic initiatives that can lead to a drug really have a lot to do, again, with some of the concepts that I've previously described.

That, you know, one, one, one has to factor in a me-medical need, once again, I'll use that term.

It's super important.

But then one also has to look at, look, here, here is our capital base, here is our timeframe, here is the competitive landscape, here is the time to push through clinic a particular drug opportunity.

And that may not always align with what-Um, you know, assets one has in order to invest in moving that drug forward.

So strategically, you have to think about that, and I can give you an example.

Have you found that to be a challenge with where you, where your company is at this stage?

Saudi Arabia was making a lot of money, and its government needed somewhere safe to invest all those earnings.

They're angry about h- how the United States conducted itself during the Arab-Israeli war, but the Saudis have traditionally relied on the United States for security guarantees, as a place to invest, as a place to do business.

So both sides have strong reasons to distrust each other, but also strong reasons to try to come back to the table.

Yeah, and you went looking, right? You've looked.

And I've been looking for a while.

But it is clear that the United States, at the very minimum, wants the Saudis and other Arab, uh, oil-rich states, and Iran as well, to continue to do at least most of their business in dollars.

They are pushing the Saudis to try to invest in US Treasury securities and in the larger US economy, both in the public sector and in the private sector.